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Privacy Rule and Family Educational Rights and Privacy Act. The Delphi technique
was used to obtain expert input for the coding document. The 131 variable coding
instrument received 93.7% agreement and a K- of .791. RESULTS: Including all
subsections, 984 laws across localities relate to immunization records. Within and
across localities, laws were grouped into 13 topic headings, including health, edu-
cation, licensing, vital statistics, and insurance. Of 36 (64%) localities that have laws
addressing IIS creation, 42% authorize and 58% require development. Locality
adoption of these laws increased 50% since the previous study. While 24 (43%)
localities have specific IIS laws, 34 (61%) have IIS provisions within other laws.
Many others may not specify IIS, but do regulate collection, sharing and/or storage
of immunization data within education, department of health or other records.
Aggregate data for the localities is presented in tabular format and shaded maps.
CONCLUSIONS: Locality IIS policies have increased, HEDIS measures incorporate
childhood immunizations, and now Meaningful Use incentives include IIS partic-
ipation. Expanding adoption of policies encouraging participation may suggest a
diffusion of innovation, through both national and state channels. As entrepreneur
localities experiment to improve IIS utility and uniformity, it will be important to
consider how the current framework has influenced participation, and opportuni-
ties for future coordination through policy development.
Infection – Research on Methods
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COMPARISON OF EVIDENCE-BASED VARIATION AND CONSTANT PERCENTAGE
VARIATION FOR ONE-WAY SENSITIVITY ANALYSES
McQueen RB, Libby A, Campbell J
University of Colorado, Aurora, CO, USA
OBJECTIVES: A common approach to one-way sensitivity analysis is to vary inputs
by a constant percentage. An alternative is to derive ranges using evidence-based
probability distributions from published sources. Our objective was to compare
one-way sensitivity analysis results when using these two approaches in the same
decisionmodel.METHODS:We replicated a published HIV/AIDS cost-effectiveness
Markov model (zidovudine vs. zidovudine plus lamivudine in the UK) using Tree-
Age®. Health states included three HIV/AIDS states and death. We generated one-
way sensitivity analyses by varying inputs in twoways: 1) using15% for all inputs,
and 2) using the 2.5 and 97.5 percentile values of the evidence-based probability
distributions for all inputs.We compared the decisionuncertainty in the incremen-
tal cost-effectiveness ratios (ICERs) for each variation method as reflected by the
difference of the lower and upper range of ICERs for all inputs. Our outcome of
interestwas themeandifference in ICERuncertaintybetweeneachmethod for the ten
most influential inputs. Additionally, we assessed the number of inputs that would
have led to an inconclusive decision for eachmethodwherehighdecisionuncertainty
exists (e.g., in this example, a willingness-to-pay (WTP) of £10,000/QALY). RESULTS:
The deterministic ICER was £7,654/QALY for combination therapy vs. mono-
therapy. Themean difference in ICER uncertainty for the evidence-based vs.15%
variation method was £3,251/QALY (p0.0096). At a WTP of £10,000/QALY, four
inputs would have led to an inconclusive decision to adopt combination therapy
using the evidence-based variation method compared to no inputs using the con-
stant percentage variation method. CONCLUSIONS: In this case, the magnitude of
uncertainty in the outcome was larger for the evidence-based variation method
compared to the constant percentage variation method. Evidence-based uncer-
tainty in inputs should be used in all sensitivity analyses to reflect realistic uncer-
tainty in an outcome and aid decision-making about future research strategies.
Muscular-Skeletal Disorders – Clinical Outcomes Studies
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DO BISPHOSPHONATES CAUSE ATYPICAL FEMUR FRACTURES?
Mann J, Talbert J
University of Kentucky, Lexington, KY, USA
OBJECTIVES: Clinical case reports support the occurrence of atypical fractures
while Phase III trials for bisphosphonates have not shown this adverse effect. This
study determines whether or not atypical fractures of the subtrochanteric region
and diaphyseal femur are occurring in bisphosphonate users within the Kentucky
Medicaid population. The incidence of atypical femur fractures in bisphosphonate
users has been estimated at 30 per 100,000 person years.1 Bisphosphonates are
commonly prescribed for the prevention of osteoporosis-related fractures,2 but
there are concerns about this possible, but rare, adverse event related to the long-
term use of bisphosphonates.3,4 METHODS: The retrospective Kentucky Medicaid
claims based study assesses the risk of atypical fracture in bisphosphonate treated
patients versus non-bisphosphonate treated patients, who experienced a baseline
fracture. Of the 19,988 patients, aged 45-95, 2,440 of them used a bisphosphonate
for at least 180 days. RESULTS: There were 209 patients experiencing an atypical
fracture. Baseline fractures were grouped and those experiencing atypical frac-
tures versus those who didn’t are as follows: humerus (1.95% vs 0.97%), lower
extremity (3.04% vs 0.97%) and vertebral (1.58% vs 0.95%). Unadjusted analysis
indicated that bisphosphonate users are two times more likely to have atypical
fracture (OR: 2.2271 95% CI: 1.6123-3.0758). Adjusting for demographics, baseline
fracture, Charlson comorbidity index, and use of corticosteroids the patients who
used a bisphosphonate for at least 6 months were 1.92 times more likely to have
atypical fracture than non-users (95% CI: 1.365-2.688). Age was a significant predic-
tor in themultivariatemodel; bisphosphonate users, 65 and older,were three times
more likely to have an atypical fracture (OR: 3.187 p value0.001). CONCLUSIONS:
While a relationship between bisphosphonate use and atypical fractures is pres-
ent, the preventative function of other fractures dictates continued therapy. How-
ever, more research is needed to determine if a certain subtype of patients can be
identified to prevent future atypical fractures.
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ATRIAL FIBRILLATION IN OSTEOPOROTIC WOMEN TREATED WITH
ALENDRONATE
Chang LC1, Kao YH1, Hsiao FY2, Tsai YW1, Huang WF1
1Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan,
2National Taiwan University, Taipei, Taiwan
BACKGROUND: Bisphosphonates have been associated with an increased risk of
atrial fibrillation (AF) and may thus be associated with an increased risk of cardio-
vascular (CV) events. However, recent studies have so far not confirmed the poten-
tial risk of CV events associated with bisphosphonate use. In addition, whether the
CV risk associated with continuous bisphosphonate use remains an unanswered
clinical question. OBJECTIVES: The purpose of this study was to assess the CV risk
including AF, stroke, or acute myocardial infarction in osteoporotic women ex-
posed to oral bisphosphonates for at least three months.METHODS:We used the
2000-2008 Taiwan’s National Health Insurance Program to conduct a popula-
tion-based, cross-over study of 10,572 newly diagnosed osteoporotic women.
Eligible patients were those who had taken alendronate, 10 mg or 70 mg, for at
least three months. Study subjects were further categorized into continuous
and discontinued users. Cox proportional models were used to compare the
1-year risk of CV events between continuous and discontinued users. RESULTS:
Among the 10,572 osteoporotic women, 8,852 received a weekly regimen of
alendronate 70 mg while 1720 received a daily regimen of alendronate 10mg.
More than 80% of alendronate users continued their therapy after the first three
months. The cumulative exposure of alendronate were 285 and 104 days (alen-
dronate 70mg) and 251 and 96 days (alendronate 10mg) in continuous and dis-
continued users, respectively. Compared to discontinued user, continuous
use of alendronate was not associated with a higher risk of CV events.
These findings were consistent among the users of alendronate 70mg
(HR1.06, 95%CI0.80-1.39) and alendronate 10mg (HR0.67, 95%CI0.42-1.06).
CONCLUSIONS: Continuous alendronate use was not significantly associated with
an increased CV risk in osteoporotic women.
PMS3
RISK FACTORS FOR NON-INITIATION OF DISEASE MODIFYING
ANTI-RHEUMATIC DRUGS (DMARD) BY PATIENTS WITH NEWLY
DIAGNOSED RHEUMATOID ARTHRITIS (RA)
Bonafede M1, Johnson BH2, Fox KM3, Watson C4, Gandra SR5
1Thomson Reuters, Andover, MA, USA, 2Thomson Reuters, Washington, DC, USA, 3Strategic
Healthcare Solutions, LLC, Monkton, MD, USA, 4Amgen, Inc., Newbury Park, CA, USA, 5Amgen,
Inc., Thousand Oaks, CA, USA
OBJECTIVES: To evaluate adoption of treatment guidelines recommending the ini-
tiation of a DMARD within 12 months of new RA diagnosis and to identify risk
factors for non-initiation. METHODS: Newly diagnosed adult RA patients from
2003-2009 with 12 months of continuous enrollment before and after their first RA
diagnosis were identified in the MarketScan Research Databases®. Patients were
excluded if they used a biologic or conventional DMARD prior to their first diagno-
sis. Patients were categorized as DMARD initiators or non-initiators in the 12
months following diagnosis (follow-up period). We compared demographic and
clinical characteristics of initiators versus non-initiators using Cox-proportional
hazard models. RESULTS: A total of 26,911 patients met the study criteria; 17,014
patients (63%) initiated a DMARD therapy in the follow-up period. At baseline, com-
pared to initiators, non-initiators were older [mean age 62.6 (SD14.9) versus 58.1
(SD13.3), p0.001], had a higher Deyo-Charlson Comorbidity Index Score (CCI) [0.76
(SD1.3) versus 0.58 (SD1.1), p0.001],weremore likely tohavehadan inpatient stay
in the pre-index period (19% versus 13%, p0.001), had higher pre-index total costs
[$12,725 (SD$24,500) versus $10,534 (SD$20,259), p0.001] and had similar out-of-
pocket total costs [$1,224 (SD$1,370) versus $1,230 (SD$1,519), p0.738)] and out-
of-pocket outpatient pharmacy costs [$492 (SD$611) versus $478 (SD$553),
p0.052]. Multivariate-adjusted risk factors for DMARD non-initiation included older
age (85), high CCI (3), and the presence of GI disorders, cardiac conditions, hyper-
tension, osteoarthritis, or respiratory infections in the pre-index period. Patients who
used an NSAID or corticosteroid, were diabetic, saw a rheumatologist, or had a rheu-
matoid factor test in the pre-index period were all more likely to initiate a DMARD in
the follow-up period. CONCLUSIONS: The majority of new RA patients followed
treatment guidelines and initiated a DMARD therapy; nevertheless, over one-third
of the patients did not initiate DMARD therapy within a year after diagnosis.
PMS4
THE ASSOCIATION BETWEEN TERIPARATIDE PERSISTENCE AND FRACTURE
OUTCOMES IN A US CLAIMS DATABASE
Yu S1, Foster S2, Burge R2, Anderson J2, Gelwicks S2, Meadows E2
1University of Illinois at Chicago, Chicago, IL, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To evaluate the association between persistence on teriparatide
(TPTD) treatment and fracture incidence rate and fracture risk among US patients.
METHODS: We used the Thomson Reuters MarketScan® Research Databases,
2004-2008, to identify new TPTD users 18 years with continuous medical and
pharmacy coverage over 12-months pre-index and 24-months post-index date (in-
dex datefirst TPTD prescription). Pathologic fractures, traumatic or clustered
fracture events (3) occurring within 7 days, fractures within 90 days of index date
or at the same site, and any hip fractures after 2nd occurrence were excluded from
the post-index osteoporotic fracture definition. Persistence was measured as total
days on TPTD until first 45-day gap. Logistic regressions were performed to model
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fracture risk for any fractures (AF), hip fractures (HF), vertebral fractures (VF), and
non-vertebral fractures (NVF) separately, controlling for patient characteristics,
insurance type, health care provider type, Charlson comorbidity index score, pre-
index bone mineral density test, medication use and fracture history. RESULTS:
Among the 3587 new TPTD users (mean age 68.9 years; 91% female), adjusted inci-
dence rates per 1000 patient years by fracture type (for persistence groups 1-6months,
7-12months, 13-18months, 19-24months)were: AF 103.09, 78.17, 72.68, 59.31; HF 6.87,
6.11, 4.30, 3.76; VF 26.29, 15.62, 11.55, 9.57; and NVF 70.90, 60.29, 60.24, 48.60. Fracture
risk was significantly higher for persistence 6 months versus 19-24 months in all
fracture models (OR1.75 [AF], 2.67 [VF], and 1.41 [NVF]), except for HF (OR1.95,
p0.078). Other significant risk factors included: older age (HF (OR1.06, p0.001) and
VF (OR1.04, p0.001); previous anticonvulsant use (VF (OR2.20, p0.001), VF
(OR1.79, p0.001)); previous immunosuppressant use (NVF (OR1.54, p0.013)); and
pre-index fracture (AF (OR1.37, p0.005); NVF (OR1.71, p0.001)). CONCLUSIONS:
Among US teriparatide patients, fracture incidence rates and fracture risk decreased
as persistence increased for any clinical, vertebral, and non-vertebral fractures.
PMS5
PERSISTENCE WITH BISPHOSPHONATE THERAPY AND RISK OF HIP FRACTURE
Chodick G1, Shalev V1, Sharon Y2, Goldstein I1
1Maccabi Healthcare Services, Tel Aviv, Israel, 2Tel Aviv University, Tel Aviv, Israel
OBJECTIVES: to investigate the association between persistence with bisphospho-
nates therapy and the risk of hip fracture in a large cohort of adult women.
METHODS: A retrospective cohort study using the database of Maccabi Healthcare
Services, a 2-million member health maintenance organization in Israel. Persis-
tence with bisphosphonates therapy was assessed by calculating the proportion of
days covered (PDC). Patients included women aged 60 years or above initiating an
oral bisphosphonates for osteoporosis between 2002 and 207. RESULTS: The inci-
dence density rate of hip fractures during study follow-up period was 4 per 1000
person-years among the 8741 patients meeting study eligibility criteria. We found
an inverse relation between persistence with bisphosphonates and hip fracture
rate. Women covered with bisphosphonates for at least 75% of the time, had a
hazard ration of 0.65 (95% confidence interval: 0.05-2.3) for hip fracture, compared
to women covered with bisphosphonates for less than 25% of the time..
CONCLUSIONS:We found a suggestive negative relation between persistence with
osteoporosis treatment and long term risk of hip fracture.
PMS6
THE PREVALENCE OF BONE FRACTURES IN OSTEOPOROSIS PATIENTS USING
PROTON PUMP INHIBITORS
Choi IS, McGuire M, Park HK, Suh DC
Rutgers University, Piscataway, NJ, USA
OBJECTIVES: To estimate the prevalence and risk factors associated with fracture
events in osteoporosis patients using proton pump inhibitor (PPI) therapy.
METHODS: This analysis utilized data from the 2001-2008 Medical Expenditure
Panel Surveys. Patients were identified if they were 50 years old, reported
having osteoporosis (ICD-9-CM code of 733 or clinical classification of 206). The
identified patients were classified into two groups depending on use of PPI.
Medications considered were osteoporosis medications (e.g., bisphosphanates,
hormone therapy, and raloxifene) and corticosteroids (excluding topical formu-
lations). Fractures were identified based on ICD-9-CM codes of 804-829. Preva-
lence of fractures was compared between two groups. Factors influencing risk of
fracture were identified through multivariable logistic regression after adjust-
ing for patient characteristics, use of medications, and comorbidities such as
heart disease, hypertension, nephropathy, depression, arthritis, epilepsy, dia-
betes, stroke, and cancer. RESULTS: We identified 4,979 patients with osteopo-
rosis, of which 970 were using PPIs and 4,009 patients were not. The majority of
the study patients were composed of females (91.4%) and non-smokers (89.6%).
Corticosteroids were used in 20.7% of the patients and osteoporosis medications
in 61.8% of patients. Bisphosphonates were the most commonly used agent in
49.2% of patients. Fractures were more prevalent in patients with PPI compared
to patients without (11.3% vs. 7.5%; p.003). Patients with PPI had a higher
likelihood of having a fracture than patients without PPI (OR1.53; p.009).
Other factors increasing risk of fractures were increasing age, heart disease,
hypertension, and stroke. CONCLUSIONS: PPI use in osteoporosis patients in-
creased the prevalence and risk of fractures. The results add to the growing body
of evidence supporting increased risk of fractures in osteoporosis patients
treated with a PPI. Additional research is recommended to investigate incidence
of fracture caused by use of PPI in osteoporosis patients.
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THE IMPACT OF RHEUMATOID ARTHRITIS ON CARDIOVASCULAR MORBIDITY
IN A HIGH RISK MEDICAID POPULATION
Shaya FT1, Yan X2, Johnson WR3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland,
Baltimore, MD, USA, 3University of Maryland School of Medicine, Baltimore, MD, USA
OBJECTIVES: Patientswith Rheumatoid Arthritis (RA) experience excess cardiovas-
cular (CVD) morbidity andmortality. RA puts patients at twice the risk for myocar-
dial infarction (MI) and stroke, younger patients being at higher risk.We investigate
the impact of RA on CVD morbidity in a high risk Medicaid managed care popula-
tion, largely female, African American, young adults, with baseline risk factors of
hypertension and diabetes. METHODS: Maryland Medicaid claims data for pa-
tients with diabetes and/or hypertension, from January 2001-June 2006 were
analyzed. Using exploratory analysis, we assessed the prevalence of RA and of
CVD, as well as the prevalence of CVD within the RA population. Logistic regres-
sion analysis was used to explore the joint impact of RA, demographics, hyper-
tension and diabetes on the likelihood of having a CVD event. RESULTS: The
prevalence RA was 2.2% among patients at high-risk for CVD. Patients with RA
were significantly older (mean age 49 vs. 34, p0.0001), largely females (80% vs.
64%, p0.0001) and non-African American (55% vs. 59%, p0.0001) than those
without RA. CVD prevalence was significantly higher in the RA population
among compared to the general population (37% vs. 17%). After adjusting for
demographics (age, gender, race) and risk factors (hypertension, diabetes), RA
significantly increased the likelihood of CVD events (OR: 1.539, 95% CI: 1.416-
1.674). In the adjusted model, hypertension (OR: 3.227) and diabetes (OR: 2.035)
also independently increased the likelihood of CVD events. CONCLUSIONS: We
found that RA independently increased cardiovascular risk by 1.5 times, in a Med-
icaid population with high baseline risk.
Muscular-Skeletal Disorders – Cost Studies
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THE BUDGET IMPACT OF LOWER GPA ADHERENCE IN PATIENTS WITH
CHRONIC NON-STEROIDAL AND COX-2 INHIBITOR USE
Bonafede M1, Johnson BH2, Crawley J3, Hellmund R3
1Thomson Reuters, Andover, MA, USA, 2Thomson Reuters, Washington, DC, USA, 3AstraZeneca
Pharmaceuticals LP, Wilmington, DE, USA
OBJECTIVES: To evaluate the budget impact of adherence to concomitant gastro-
protective (GPA) therapy among patients using non-selective non-steroidals (ns-
NSAIDs) or COX-2 inhibitors (COXIBs) at high risk for NSAID-induced upper gastro-
intestinal (UGI) complications. Clinical guidelines recommend that patients at high
risk for UGI complications using ns-NSAIDs or COXIBs for arthritis pain manage-
ment should concomitantly take GPA; however, GPA use and adherence are often
low and associated with an increase in UGI events.METHODS: The impact of GPA
adherence was assessed using a budget impact model with a one-year time hori-
zon. UGI risk is a function of patient (age, previous ulcer history, concomitant low
dose aspirin use) and treatment (ns-NSAID or COXIB, concomitant GPA use and
adherence) characteristics. A mean GPA adherence rate of 51% was derived from
theMarketScan Research Databases, using a sample of patients50 years old with
at least 2 prescriptions for ns-NSAIDs or COXIBs from 2001 through 2007
(N738,248). Treatment-specific UGI event rates and costs were taken from the
literature for dyspepsia, symptomatic ulcers and UGI bleeding. Sensitivity analysis
was performed around the model inputs. RESULTS: In the base case analysis,
NSAID-induced UGI events are responsible for $9,328,857 in direct medical costs
annually in a hypothetical health plan with 100,000 members, where 21.6% of
patients are on chronic ns-NSAID or COXIB therapy for arthritis and 82% of these
patients are at increased risk of a UGI event due to age, previous ulcer history, or
both. Increasing GPA adherence to 75% decreases NSAID-induced UGI event costs
by $547,074, or -$0.45 per-member-per-month (PMPM) in a 100,000-member health
plan; reducing GPA adherence to 25% increases these costs by $737,834 ($0.62
PMPM). CONCLUSIONS: GPA adherence has a strong impact on the cost associated
with NSAID-induced UGI events. This finding was consistent throughout sensitiv-
ity analyses varying risk factors and costs of UGI events.
PMS9
COST CONSEQUENCE OF COLCHICINE APPROVAL IN THE MEDICAID PROGRAMS
IN THE UNITED STATES
Zhang YJ, Kelton C, Guo JJ
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: In 2009, the price of colchicine, an anti-gout agent that is also used to
treat familial Mediterranean fever, skyrocketed, surprising physicians, patients,
and payers. Objectives are to (1) determine the cost consequence to the U.S. Med-
icaid programs of this price rise and (2) explain why it occurred. METHODS: Med-
icaid drug utilization data were used to identify all colchicine products from 2000
quarter 1 through 2010 quarter 1. The first five digits of each product’s NDC code
were used to identify the manufacturer. A retrospective, descriptive analysis was
conducted to determine the trends of colchicine utilization (prescriptions and tab-
lets), spending (in 2009 US$), and reimbursement per tablet as a proxy for price.
RESULTS:Colchicine utilization byMedicaid enrollees increased from 2000 to 2005,
reaching 417,000 prescriptions (18million tablets, $4.5million). FollowingMedicare
Part D and the movement of dual eligibles from Medicaid to Medicare, Medicaid
colchicine utilization dropped 72% in terms of number of prescriptions. The aver-
age spending for colchicine not marketed by URL Pharma increased from $0.27 per
tablet in 2000–2009 to $0.35 in the first quarter of 2010 (30% increase), while the
Colcrys® price (URL’s branded drug) rose from $0.29 in 2000–2008 to $3.79 in 2009–
2010 (12-fold increase). It is estimated that an additional $21million could be added
to Medicaid spending if all patients on single-ingredient colchicine treatment
switched to Colcrys®. CONCLUSIONS: The rise in price is an unintended conse-
quence of a drug-safety initiative launched in June 2006 by the U.S. Food and Drug
Administration (FDA) to phase out unapproved drugs, including single-ingredient
oral colchicines. Meanwhile, the FDA granted approval to URL Pharma in July 2009,
inadvertently creating a monopoly in the anti-gout market. If additional drugs are
not approved to stimulate competition, a substantial financial burden will be
placed on patients and taxpayers.
PMS11
APPLYING THE STRATIFIED PROPENSITY SCORE MATCHING METHOD WHEN
ESTIMATING HEALTH CARE COSTS OF RHEUMATOID ARTHRITIS PATIENTS
Baser O, Xie L
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To apply the stratified propensity score matching technique to esti-
mate the healthcare costs of rheumatoid arthritis (RA) patients. METHODS: Con-
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